Marianne Noone

1.3k total citations
22 papers, 971 citations indexed

About

Marianne Noone is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Marianne Noone has authored 22 papers receiving a total of 971 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Marianne Noone's work include Cancer Treatment and Pharmacology (10 papers), Neutropenia and Cancer Infections (4 papers) and HER2/EGFR in Cancer Research (3 papers). Marianne Noone is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Neutropenia and Cancer Infections (4 papers) and HER2/EGFR in Cancer Research (3 papers). Marianne Noone collaborates with scholars based in United States, Switzerland and United Kingdom. Marianne Noone's co-authors include Kenneth H. Cowan, Andrea Denicoff, Barry R. Goldspiel, Joyce O’Shaughnessy, Anthony W. Tolcher, David Venzon, Frederick P. Ognibene, Stacey L. Berg, Frank M. Balis and David Köhler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Marianne Noone

22 papers receiving 932 citations

Peers

Countries citing papers authored by Marianne Noone

Since Specialization

Citations

This map shows the geographic impact of Marianne Noone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marianne Noone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marianne Noone more than expected).

Fields of papers citing papers by Marianne Noone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marianne Noone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marianne Noone. The network helps show where Marianne Noone may publish in the future.

Co-authorship network of co-authors of Marianne Noone

This figure shows the co-authorship network connecting the top 25 collaborators of Marianne Noone. A scholar is included among the top collaborators of Marianne Noone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marianne Noone. Marianne Noone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Digital Health Technologies in Pediatric Trials 2022 ·Therapeutic Innovation & Regulatory Science ·Leonard Sacks, (unknown), Marianne Noone	5
2	The Role of User Input in Shaping Online Information From the National Cancer Institute 2005 ·Journal of Medical Internet Research ·(unknown), Margaret Beckwith, (unknown), (unknown), (unknown), (unknown), Marianne Noone, Deborah Price, (unknown), (unknown), Lawrence W. Wright	19
3	Fatal Pasteurella dagmatis peritonitis and septicaemia in a patient with cirrhosis: a case report and review of the literature 2004 ·Journal of Clinical Pathology ·(unknown), Marianne Noone, A D Dwarakanath, H. Malnick	27
4	A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. 2001 ·PubMed ·Elise C. Kohn, E Reed, Gisele Sarosy, Lori M. Minasian, Kenneth S. Bauer, Benjamín C. Bostick, (unknown), (unknown), A Tompkins, Marianne Noone, Barry R. Goldspiel, James M. Pluda, William D. Figg, Lance A. Liotta	48
5	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer 2001 ·Seminars in Oncology ·William D. Figg, (unknown), James L. Gulley, Patricia Fernández, Marianne Noone, (unknown), Michael C. Hamilton, Catherine Parker, Erwin A. Kruger, James M. Pluda, William L. Dahut	11
6	Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations 2001 ·Journal of Clinical Oncology ·Julia Lawrence, Peter C. Adamson, Rafael C. Caruso, Catherine Chow, David E. Kleiner, Robert F. Murphy, David Venzon, Margaret Shovlin, Marianne Noone, Maria J. Merino, Kenneth H. Cowan, (unknown), Joyce O’Shaughnessy, JoAnne Zujewski	39
7	Pilot Trial of the Safety, Tolerability, and Retinoid Levels of N-(4-hydroxyphenyl) Retinamide in Combination With Tamoxifen in Patients at High Risk for Developing Invasive Breast Cancer 2000 ·Journal of Clinical Oncology ·Barbara A. Conley, Joyce O’Shaughnessy, Sheila A. Prindiville, Julia Lawrence, Catherine Chow, Elizabeth C. Jones, Maria J. Merino, Muriel I. Kaiser‐Kupfer, Rafael C. Caruso, Marvin J. Podgor, Barry R. Goldspiel, David Venzon, David N. Danforth, Suhlan Wu, Marianne Noone, Jennifer Goldstein, Kenneth H. Cowan, JoAnne Zujewski	55
8	Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer 1998 ·Annals of Surgical Oncology ·David N. Danforth, JoAnne Zujewski, Joyce O’Shaughnessy, David Riseberg, Seth M. Steinberg, Nanette McAtee, Marianne Noone, Catherine Chow, (unknown), Marc E. Lippman, Joan Jacobson, Paul Okunieff, Kenneth H. Cowan	33
9	Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. 1996 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Kenneth H. Cowan, D. Solomon, Frederick P. Ognibene, Barry R. Goldspiel, Richard Chang, Marianne Noone, Andrea Denicoff, (unknown), (unknown), Patricia Fetsch, Stacey L. Berg, Frank M. Balis, David Venzon, Joyce O’Shaughnessy	61
10	Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. 1996 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Kenneth H. Cowan, Marianne Noone, Andrea Denicoff, David Köhler, Barry R. Goldspiel, (unknown), Mary S. McCabe, (unknown), Jo Anne Zujewski, J. O’Shaughnessy	26
11	Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow 1996 ·British Journal of Haematology ·Gretchen N. Schwartz, Frances T. Hakim, J. Zujewski, (unknown), (unknown), David Riseberg, M K Warren, Crystal L. Mackall, (unknown), Marianne Noone, K H Cowan, J. O’Shaughnessy, Ronald E. Gress	9
12	Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. 1996 ·Journal of Clinical Oncology ·Jason S. Fisherman, K H Cowan, Marianne Noone, Andrea Denicoff, Stacey L. Berg, David G. Poplack, Frank M. Balis, David Venzon, Mary S. McCabe, Barry R. Goldspiel, C. Chow, Frederick P. Ognibene, Joyce O’Shaughnessy	60
13	Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer 1996 ·Blood ·J. O’Shaughnessy, Anthony W. Tolcher, David Riseberg, David Venzon, J. Zujewski, Marianne Noone, (unknown), David N. Danforth, James W. Jacobson, Victoria Chang, Barry R. Goldspiel, Patricia Keegan, Ruthann M. Giusti, (unknown)	26
14	Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. 1995 ·PubMed ·Lalage M. Wakefield, John J. Letterio, (unknown), David Danielpour, R. S. Allison, Lee H. Pai, Andrea Denicoff, Marianne Noone, Kenneth H. Cowan, J. O’Shaughnessy	139
15	Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. 1995 ·Journal of Clinical Oncology ·Stacey L. Berg, Anthony W. Tolcher, Joyce O’Shaughnessy, Andrea Denicoff, Marianne Noone, Frederick P. Ognibene, Kenneth H. Cowan, Frank M. Balis	63
16	Retroviral Mediated Transfer of the Human Multidrug Resistance Gene (MDR-1) into Hematopoietic Stem Cells During Autologous Transplantation after Intensive Chemotherapy for Metastatic Breast Cancer. National Institutes of Health, Bethesda, Maryland 1994 ·Human Gene Therapy ·Joyce O’Shaughnessy, Kenneth H. Cowan, Arthur W. Nienhuis, Kevin T. McDonagh, Brian P. Sorrentino, Cynthia E. Dunbar, Ya‐Wen Chiang, Wyndham H. Wilson, Barry R. Goldspiel, David Köhler, Michele Cottler‐Fox, Susan F. Leitman, Michael M. Gottesman, Ira Pastan, Andrea Denicoff, Marianne Noone, Ronald E. Gress	58
17	A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients 1994 ·Annals of Oncology ·Joyce O’Shaughnessy, Andrea Denicoff, David Venzon, David N. Danforth, Lori J. Pierce, James N. Frame, Anne Bastian, Bimal C. Ghosh, Barry R. Goldspiel, L.L. Miller, F. Andrew Dorr, Patricia Keegan, (unknown), (unknown), Marianne Noone, Kenneth H. Cowan	24
18	Phase I study of taxol plus doxorubicin plus granulocyte colony-stimulating factor (G-CSF) in patients with metastatic breast cancer 1993 ·European Journal of Cancer ·J. O’Shaughnessy, Jason S. Fisherman, Mary S. McCabe, Marianne Noone, (unknown)	4
19	Nursing management of the patient receiving Taxol therapy. 1993 ·PubMed ·Marianne Noone, Mary S. McCabe, Andrea Denicoff, J. McCarthy Lepore	3
20	Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. 1993 ·PubMed ·(unknown), Mary S. McCabe, Marianne Noone, (unknown), Barry R. Goldspiel, (unknown), (unknown), J. O’Shaughnessy	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact